Buys | $0 | 0 | 0 |
Sells | $6,720,817 | 16 | 100 |
Chinoporos Constantine | See Remarks | 0 | $0 | 2 | $17,348 | $-17,348 |
Hansard Adam | Chief Commercial Officer | 0 | $0 | 1 | $263,415 | $-263,415 |
Funtleyder Leslie D. | Chief Financial Officer | 0 | $0 | 5 | $327,452 | $-327,452 |
Perfetti Riccardo | Chief Medical Officer | 0 | $0 | 5 | $881,585 | $-881,585 |
ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 0 | $0 | 2 | $1.27M | $-1.27M |
Shendelman Shoshana | President and CEO | 0 | $0 | 5 | $6.7M | $-6.7M |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III …
Over the last 12 months, insiders at Applied Therapeutics, Inc. have bought $0 and sold $6.72M worth of Applied Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Applied Therapeutics, Inc. have bought $661,035 and sold $8.75M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $65,367 was made by Kanter Stacy J. (director) on 2023‑12‑01.
2025-03-04 | Sale | Perfetti Riccardo | Chief Medical Officer | 10,366 0.0081% | $0.44 | $4,561 | +6.39% | |
2025-03-04 | Sale | Funtleyder Leslie D. | See Remarks | 14,502 0.0114% | $0.44 | $6,381 | +6.39% | |
2025-03-04 | Sale | Chinoporos Constantine | See Remarks | 447 0.0004% | $0.44 | $197 | +6.39% | |
2025-02-06 | Sale | Perfetti Riccardo | Chief Medical Officer | 86,078 0.0743% | $0.61 | $52,508 | -10.83% | |
2025-02-06 | Sale | Funtleyder Leslie D. | See Remarks | 22,950 0.0198% | $0.61 | $14,000 | -10.83% | |
2025-02-06 | Sale | Chinoporos Constantine | See Remarks | 28,117 0.0243% | $0.61 | $17,151 | -10.83% | |
2024-08-22 | Sale | Perfetti Riccardo | Chief Medical Officer | 22,681 0.0206% | $5.83 | $132,230 | -68.75% | |
2024-08-22 | Sale | Funtleyder Leslie D. | Chief Financial Officer | 13,530 0.0123% | $5.83 | $78,880 | -68.75% | |
2024-08-14 | Sale | Shendelman Shoshana | President and CEO | 119,591 0.1056% | $5.93 | $709,175 | -20.78% | |
2024-08-13 | Sale | Shendelman Shoshana | President and CEO | 357,423 0.3288% | $6.18 | $2.21M | -22.20% | |
2024-08-12 | Sale | Shendelman Shoshana | President and CEO | 300,000 0.267% | $5.98 | $1.79M | -16.30% | |
2024-06-06 | Sale | Shendelman Shoshana | President and CEO | 61,795 0.0519% | $4.32 | $266,954 | +13.33% | |
2024-06-06 | Sale | Perfetti Riccardo | Chief Medical Officer | 22,003 0.0185% | $4.32 | $95,053 | +13.33% | |
2024-06-06 | Sale | Funtleyder Leslie D. | Chief Financial Officer | 16,980 0.0143% | $4.32 | $73,354 | +13.33% | |
2024-06-05 | Sale | ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 150,000 0.1261% | $4.24 | $636,000 | +15.16% | |
2024-06-04 | Sale | ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 150,000 0.131% | $4.21 | $631,500 | +20.38% | |
2024-03-14 | Sale | Shendelman Shoshana | President and CEO | 318,573 0.2652% | $5.39 | $1.72M | -16.07% | |
2024-03-14 | Sale | Perfetti Riccardo | Chief Medical Officer | 110,804 0.0922% | $5.39 | $597,234 | -16.07% | |
2024-03-14 | Sale | Hansard Adam | Chief Commercial Officer | 48,871 0.0407% | $5.39 | $263,415 | -16.07% | |
2024-03-14 | Sale | Funtleyder Leslie D. | Chief Financial Officer | 28,727 0.0239% | $5.39 | $154,839 | -16.07% |
ALEXANDRIA REAL ESTATE EQUITIES, INC. | 10 percent owner | 5855077 5.032% | $3.01M | 2 | 6 | +18.45% |
Shendelman Shoshana | President and CEO | 4690839 4.0315% | $2.41M | 6 | 15 | +32.95% |
Perfetti Riccardo | Chief Medical Officer | 890409 0.7652% | $457,135.98 | 1 | 61 | <0.0001% |
MARCUS JOEL S | director | 365360 0.314% | $187,575.82 | 2 | 3 | +10.6% |
Kanter Stacy J. | director | 63000 0.0541% | $32,344.20 | 3 | 0 | +15.24% |
$2,942,496 | 100 | 17.32% | $66.91M | |
$6,787,959 | 35 | 49.84% | $60.62M | |
$22,110,933 | 34 | 30.18% | $67.48M | |
$459,011,221 | 33 | 33.04% | $57.94M | |
$144,247,213 | 29 | 10.15% | $64.24M |
Increased Positions | 86 | +59.31% | 41M | +36.28% |
Decreased Positions | 67 | -46.21% | 38M | -33.86% |
New Positions | 42 | New | 3M | New |
Sold Out Positions | 43 | Sold Out | 8M | Sold Out |
Total Postitions | 164 | +13.1% | 115M | +2.42% |
Vestal Point Capital, Lp | $5,900.00 | 9.91% | 11.5M | +10M | +904.37% | 2024-12-31 |
Vr Adviser, Llc | $5,125.00 | 8.61% | 9.99M | +165,591 | +1.69% | 2024-12-31 |
Propel Bio Management, Llc | $4,933.00 | 8.29% | 9.62M | +3M | +46.4% | 2024-12-31 |
Blackrock, Inc. | $4,769.00 | 8.01% | 9.3M | +2M | +33.9% | 2024-12-31 |
Morgan Stanley | $4,522.00 | 7.6% | 8.82M | -1M | -10.99% | 2024-12-31 |
Schonfeld Strategic Advisors Llc | $4,495.00 | 7.55% | 8.76M | +8M | +2,458.26% | 2024-12-31 |
Knoll Capital Management, Llc | $2,975.00 | 5% | 5.8M | +225,000 | +4.04% | 2024-12-31 |
Vanguard Group Inc | $2,846.00 | 4.78% | 5.55M | +305,282 | +5.82% | 2024-12-31 |
T. Rowe Price Investment Management, Inc. | $2,781.00 | 4.67% | 5.42M | +5M | +2,511.86% | 2024-12-31 |
Deutsche Bank Ag | $2,292.00 | 3.85% | 4.47M | +30,520 | +0.69% | 2024-12-31 |